Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/13/2025

Diagnosing Aspergillosis with Blood Tests

Galactomannan (GM) Testing

  • The American Thoracic Society recommends serum galactomannan testing for diagnosing invasive aspergillosis in patients with severe immunocompromise, with a strong recommendation and high-quality evidence 1, 2
  • Serum galactomannan testing is recommended for diagnosing invasive aspergillosis in patients with neutropenia, hematological malignancy, or recipients of hematopoietic stem cell or solid organ transplants, with a strong recommendation and high-quality evidence 1, 2
  • For optimal accuracy, two consecutive samples with an optical density index (ODI) ≥0.5 or retesting of the same sample is recommended 2, 3
  • Prospective monitoring should be performed every 3-4 days in high-risk patients and combined with HRCT and clinical evaluation 2, 3

Bronchoalveolar Lavage (BAL) Fluid Testing

  • BAL fluid GM testing is strongly recommended when serum GM is negative but clinical suspicion remains high, or when serum GM is positive but there are confounding factors for false-positive results 1, 2
  • BAL GM testing has excellent performance with optimal cut-off values between 0.5 and 1.0 2, 5

Other Blood Tests for Aspergillosis

  • The Infectious Diseases Society of America recommends serum (1→3)-β-D-Glucan (BDG) testing for diagnosing invasive fungal infections, including aspergillosis, in high-risk patients 1, 6
  • BDG has limited specificity for Aspergillus as it is present in many fungal species 2, 6
  • Aspergillus PCR on blood samples shows variable performance with sensitivity of 88% and specificity of 75% for a single positive test 8
  • Combined use of PCR with GM testing provides greater diagnostic accuracy 8

Diagnostic Algorithm for Invasive Aspergillosis

  • Initial screening in high-risk patients should include serum GM testing every 3-4 days in neutropenic patients or hematopoietic stem cell transplant recipients 2, 3
  • If clinical suspicion persists despite negative serum tests, perform bronchoscopy with BAL for GM testing and culture 1, 2
  • For monitoring treatment response, serial serum GM testing is recommended, with decreasing values during the first 2 weeks indicating a favorable response 2, 4